Ken Griffin’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Ken Griffin’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-69	Closed	-$41K	–	8208
2017 Q2	$41K	Buy	+69	New	+$40.3K	﹤0.01%	7144

Other funds holding VYNT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ken Griffin's VYNT Position: Q1 2023 in Review

Ken Griffin sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2023, closing a stake of 11,224 shares — an estimated $7.88K sold.

Ken Griffin first reported a position in VYNT in Q2 2016 and held it in 8 quarters. The position peaked at $97K in Q2 2021. 17 funds tracked by Wall St. Rank hold VYNT as of Q1 2023.

Ken Griffin reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Ken Griffin sold 11,224 Vyant Bio, Inc. Common Stock shares in Q1 2023, an estimated $7.88K.
Ken Griffin first reported a position in Vyant Bio, Inc. Common Stock in Q2 2016 and held it in 8 quarters.
Ken Griffin's Vyant Bio, Inc. Common Stock position peaked at $97K in Q2 2021.
17 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.